Search

Your search keyword '"Ostinelli, Edoardo G."' showing total 141 results
Start Over Author "Ostinelli, Edoardo G."
141 results on '"Ostinelli, Edoardo G."'

4. Digital Mental Health for Schizophrenia and Other Severe Mental Illnesses: An International Consensus on Current Challenges and Potential Solutions

Author

Smith, Katharine A, primary, Hardy, Amy, additional, Vinnikova, Anastasia, additional, Blease, Charlotte, additional, Milligan, Lea, additional, Hidalgo-Mazzei, Diego, additional, Lambe, Sinéad, additional, Marzano, Lisa, additional, Uhlhaas, Peter J, additional, Ostinelli, Edoardo G, additional, Anmella, Gerard, additional, Zangani, Caroline, additional, Aronica, Rosario, additional, Dwyer, Bridget, additional, Torous, John, additional, and Cipriani, Andrea, additional

Published
2024
Full Text
View/download PDF

5. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data

Author

Siafis, Spyridon, primary, Chiocchia, Virginia, additional, Macleod, Malcolm R., additional, Austin, Charlotte, additional, Homiar, Ava, additional, Tinsdeall, Francesca, additional, Friedrich, Claire, additional, Ramage, Fiona J., additional, Kennett, Jaycee, additional, Nomura, Nobuyuki, additional, Maksym, Olena, additional, Rutigliano, Grazia, additional, Vano, Luke J., additional, McCutcheon, Robert A., additional, Gilbert, David, additional, Ostinelli, Edoardo G., additional, Stansfield, Claire, additional, Dehdarirad, Hossein, additional, Juma, Damian Omari, additional, Wright, Simonne, additional, Simple, Ouma, additional, Elugbadebo, Olufisayo, additional, Tonia, Thomy, additional, Mantas, Ioannis, additional, Howes, Oliver D., additional, Furukawa, Toshi A., additional, Milligan, Lea, additional, Moreno, Carmen, additional, Elliott, Julian H., additional, Hastings, Janna, additional, Thomas, James, additional, Michie, Susan, additional, Sena, Emily S., additional, Seedat, Soraya, additional, Egger, Matthias, additional, Potts, Jennifer, additional, Cipriani, Andrea, additional, Salanti, Georgia, additional, and Leucht, Stefan, additional

Published
2024
Full Text
View/download PDF

6. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis

Author

De Crescenzo, Franco, D'Alò, Gian Loreto, Ostinelli, Edoardo G, Ciabattini, Marco, Di Franco, Valeria, Watanabe, Norio, Kurtulmus, Ayse, Tomlinson, Anneka, Mitrova, Zuzana, Foti, Francesca, Del Giovane, Cinzia, Quested, Digby J, Cowen, Phil J, Barbui, Corrado, Amato, Laura, Efthimiou, Orestis, and Cipriani, Andrea

Published
2022
Full Text
View/download PDF

10. Digital Mental Health for Schizophrenia and Other Severe Mental Illnesses: An International Consensus on Current Challenges and Potential Solutions (Preprint)

Author

Smith, Katharine A, primary, Hardy, Amy, additional, Vinnikova, Anastasia, additional, Blease, Charlotte, additional, Milligan, Lea, additional, Hidalgo-Mazzei, Diego, additional, Lambe, Sinéad, additional, Marzano, Lisa, additional, Uhlhaas, Peter J, additional, Ostinelli, Edoardo G, additional, Anmella, Gerard, additional, Zangani, Caroline, additional, Aronica, Rosario, additional, Dwyer, Bridget, additional, Torous, John, additional, and Cipriani, Andrea, additional

Published
2024
Full Text
View/download PDF

11. Components and Delivery Formats of Cognitive Behavioral Therapy for Chronic Insomnia in Adults

Author

Furukawa, Yuki, primary, Sakata, Masatsugu, additional, Yamamoto, Ryuichiro, additional, Nakajima, Shun, additional, Kikuchi, Shino, additional, Inoue, Mari, additional, Ito, Masami, additional, Noma, Hiroku, additional, Takashina, Hikari Nishimura, additional, Funada, Satoshi, additional, Ostinelli, Edoardo G., additional, Furukawa, Toshi A., additional, Efthimiou, Orestis, additional, and Perlis, Michael, additional

Published
2024
Full Text
View/download PDF

12. Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data

Author

Furukawa, Toshi A, Suganuma, Aya, Ostinelli, Edoardo G, Andersson, Gerhard, Beevers, Christopher G, Shumake, Jason, Berger, Thomas, Boele, Florien Willemijn, Buntrock, Claudia, Carlbring, Per, Choi, Isabella, Christensen, Helen, Mackinnon, Andrew, Dahne, Jennifer, Huibers, Marcus J H, Ebert, David D, Farrer, Louise, Forand, Nicholas R, Strunk, Daniel R, Ezawa, Iony D, Forsell, Erik, Kaldo, Viktor, Geraedts, Anna, Gilbody, Simon, Littlewood, Elizabeth, Brabyn, Sally, Hadjistavropoulos, Heather D, Schneider, Luke H, Johansson, Robert, Kenter, Robin, Kivi, Marie, Björkelund, Cecilia, Kleiboer, Annet, Riper, Heleen, Klein, Jan Philipp, Schröder, Johanna, Meyer, Björn, Moritz, Steffen, Bücker, Lara, Lintvedt, Ove, Johansson, Peter, Lundgren, Johan, Milgrom, Jeannette, Gemmill, Alan W, Mohr, David C, Montero-Marin, Jesus, Garcia-Campayo, Javier, Nobis, Stephanie, Zarski, Anna-Carlotta, O'Moore, Kathleen, Williams, Alishia D, Newby, Jill M, Perini, Sarah, Phillips, Rachel, Schneider, Justine, Pots, Wendy, Pugh, Nicole E, Richards, Derek, Rosso, Isabelle M, Rauch, Scott L, Sheeber, Lisa B, Smith, Jessica, Spek, Viola, Pop, Victor J, Ünlü, Burçin, van Bastelaar, Kim M P, van Luenen, Sanne, Garnefski, Nadia, Kraaij, Vivian, Vernmark, Kristofer, Warmerdam, Lisanne, van Straten, Annemieke, Zagorscak, Pavle, Knaevelsrud, Christine, Heinrich, Manuel, Miguel, Clara, Cipriani, Andrea, Efthimiou, Orestis, Karyotaki, Eirini, and Cuijpers, Pim

Published
2021
Full Text
View/download PDF

16. Towards precision in the diagnostic profiling of patients: leveraging symptom dynamics as a clinical characterisation dimension in the assessment of major depressive disorder.

Author

Ebrahimi, Omid V., Borsboom, Denny, Hoekstra, Ria H. A., Epskamp, Sacha, Ostinelli, Edoardo G., Bastiaansen, Jojanneke A., and Cipriani, Andrea

Subjects
MENTAL depression, ECOLOGICAL momentary assessments (Clinical psychology), SYMPTOMS, INDIVIDUAL differences
Abstract

Background: International guidelines present overall symptom severity as the key dimension for clinical characterisation of major depressive disorder (MDD). However, differences may reside within severity levels related to how symptoms interact in an individual patient, called symptom dynamics. Aims: To investigate these individual differences by estimating the proportion of patients that display differences in their symptom dynamics while sharing the same overall symptom severity. Method: Participants with MDD (n = 73; mean age 34.6 years, s.d. = 13.1; 56.2% female) rated their baseline symptom severity using the Inventory for Depressive Symptomatology Self-Report (IDS-SR). Momentary indicators for depressive symptoms were then collected through ecological momentary assessments five times per day for 28 days; 8395 observations were conducted (average per person: 115; s.d. = 16.8). Each participant's symptom dynamics were estimated using person-specific dynamic network models. Individual differences in these symptom relationship patterns in groups of participants sharing the same symptom severity levels were estimated using individual network invariance tests. Subsequently, the overall proportion of participants that displayed differential symptom dynamics while sharing the same symptom severity was calculated. A supplementary simulation study was conducted to investigate the accuracy of our methodology against false-positive results. Results: Differential symptom dynamics were identified across 63.0% (95% bootstrapped CI 41.0–82.1) of participants within the same severity group. The average false detection of individual differences was 2.2%. Conclusions: The majority of participants within the same depressive symptom severity group displayed differential symptom dynamics. Examining symptom dynamics provides information about person-specific psychopathological expression beyond severity levels by revealing how symptoms aggravate each other over time. These results suggest that symptom dynamics may be a promising new dimension for clinical characterisation, warranting replication in independent samples. To inform personalised treatment planning, a next step concerns linking different symptom relationship patterns to treatment response and clinical course, including patterns related to spontaneous recovery and forms of disorder progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Assessing the Impact of Evidence-Based Mental Health Guidance During the COVID-19 Pandemic: Systematic Review and Qualitative Evaluation

Author

Smith, Katharine A, primary, Ostinelli, Edoardo G, additional, Ede, Roger, additional, Allard, Lisa, additional, Thomson, Michaela, additional, Hewitt, Kiran, additional, Brown, Petra, additional, Zangani, Caroline, additional, Jenkins, Matthew, additional, Hinze, Verena, additional, Ma, George, additional, Pothulu, Prajnesh, additional, Henshall, Catherine, additional, Malhi, Gin S, additional, Every-Palmer, Susanna, additional, and Cipriani, Andrea, additional

Published
2023
Full Text
View/download PDF

19. Assessing the Impact of Evidence-Based Mental Health Guidance During the COVID-19 Pandemic: Systematic Review and Qualitative Evaluation (Preprint)

Author

Smith, Katharine A, primary, Ostinelli, Edoardo G, additional, Ede, Roger, additional, Allard, Lisa, additional, Thomson, Michaela, additional, Hewitt, Kiran, additional, Brown, Petra, additional, Zangani, Caroline, additional, Jenkins, Matthew, additional, Hinze, Verena, additional, Ma, George, additional, Pothulu, Prajnesh, additional, Henshall, Catherine, additional, Malhi, Gin S, additional, Every-Palmer, Susanna, additional, and Cipriani, Andrea, additional

Published
2023
Full Text
View/download PDF

20. Dismantling cognitive-behavioural therapy for chronic insomnia in adults with or without comorbidities: a systematic review and component network meta-analysis

Author

Furukawa, Yuki, primary, Sakata, Masatsugu, additional, Yamamoto, Ryuichiro, additional, Nakajima, Shun, additional, Kikuchi, Shino, additional, Inoue, Mari, additional, Ito, Masami, additional, Noma, Hiroku, additional, Funada, Satoshi, additional, Ostinelli, Edoardo G, additional, Furukawa, Toshi A, additional, Efthimiou, Orestis, additional, and Perlis, Michael, additional

Published
2023
Full Text
View/download PDF

23. sj-docx-1-anp-10.1177_00048674221150362 – Supplemental material for Community interventions for anxiety and depression in adults and young people: A systematic review

Author

Buechner, Hadassah, Toparlak, Sureyya M, Ostinelli, Edoardo G, Shokraneh, Farhad, Nicholls-Mindlin, Jessica, Cipriani, Andrea, Geddes, John R, and Syed Sheriff, Rebecca

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), Neuroscience
Abstract

Supplemental material, sj-docx-1-anp-10.1177_00048674221150362 for Community interventions for anxiety and depression in adults and young people: A systematic review by Hadassah Buechner, Sureyya M Toparlak, Edoardo G Ostinelli, Farhad Shokraneh, Jessica Nicholls-Mindlin, Andrea Cipriani, John R Geddes and Rebecca Syed Sheriff in Australian & New Zealand Journal of Psychiatry

Published
2023
Full Text
View/download PDF

24. Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study

Author

D'Agostino, Armando, Aguglia, Andrea, Barbui, Corrado, Bartoli, Francesco, Carrà, Giuseppe, Cavallotti, Simone, Chirico, Margherita, Ostinelli, Edoardo G, Zangani, Caroline, Martinotti, Giovanni, Ostuzzi, Giovanni, Bertolini, Federico, Calandra, Carmela, Callegari, Camilla, D’Agostino, Armando, Lucii, Claudio, Mastromo, Daniele, Moretti, Daniele, Monzani, Emiliano, Porcellana, Matteo, Prestia, Davide, Nose, Michela, Purgato, Marianna, Turrini, Giulia, Mazzi, Maria, Angela, Papola, Davide, Gastaldon, Chiara, Terlizzi, Samira, Piccoli, Alberto, Ruggeri, Mirella, De Fazio, Pasquale, Magliocco, Fabio, Caroleo, Mariarita, Raffaele, Gaetano, Ostinelli, Edoardo, Giuseppe, Bolognesi, Simone, Debolini, Sara, Pierantozzi, Elisa, Fargnoli, Francesco, Del Zanna, Maria, Giannini, Alessandra, Luccarelli, Livia, De Capua, Alberto, Annese, Pasqua, Maria, Cerretini, Massimiliano, Tozzi, Fiorella, Magnani, Nadia, Cardamone, Giuseppe, Bardicchia, Francesco, Facchi, Edvige, Soscia, Federica, Zotos, Spyridon, Biancosino, Bruno, Zonta, Filippo, Pompei, Francesco, Zizolfi, Daniele, Ielmini, Marta, Caselli, Ivano, Giana, Edoardo, Buzzi, Aldo, Emanuele, Diurni, Marcello, Milano, Anna, Sani, Emanuele, Calzolari, Roberta, Bortolaso, Paola, Piccinelli, Marco, Cazzamalli, Sara, Caterina, Alberini, Gabro, Piantanida, Silvia, Costantini, Chiara, Paronelli, Chiara, Di Caro, Angela, Moretti, Valentina, Gozzi, Mauro, D'Ippolito, Chiara, Barbanti Silva, Veronica, Papalini, Alessandro, Corbo, Mariangela, Campese, Ornella, Fiori, Federica, Lorusso, Marco, Di Capro, Lucia, Viceconte, Daniela, Mancini, Valerio, Suraniti, Francesco, Signorelli, Maria, Salvina, Rossi, Eugenio, Lupoli, Pasqualino, Menchetti, Marco, Terzi, Laura, Boso, Marianna, Risaro, Paolo, De Paoli, Giuseppe, Catania, Cristina, Tarricone, Ilaria, Caretto, Valentina, Storbini, Viviana, Emiliani, Roberta, Balzarro, Beatrice, Carra, Giuseppe, Tabacchi, Tommaso, Nava, Roberto, Bono, Adele, Provenzi, Milena, Brambilla, Giulia, Aspesi, Flora, Tremolada, Martina, Castagna, Gloria, Bava, Mattia, Verrengia, Enrica, Lucchi, Sara, Oriani, Maria, Ginevra, Barchiesi, Michela, Pacetti, Monica, Magni, Laura, Rosa, Rossi, Giuseppe, Beneduce, Rossella, Tura, Giovanni, Battista, Laffranchini, Laura, Ferrato, Farida, Restaino, Francesco, Limosani, Ivan, Ghio, Lucio, Ferro, Maurizio, Parise, Vincenzo, Fricchione, Balletta, Giovanni, Addeo, Lelio, De Vivo, Elisa, Di Benedetto, Rossella, Pinna, Federica, Carpiniello, Bernardo, Spano, Mariangela, Giacomin, Marzio, Pecile, Damiano, Mattei, Chiara, Fabrici, Elisabetta, Pascolo, Panarello, Sofia, Peresson, Giulia, Vitucci, Claudio, Bonavigo, Tommaso, Perini, Giovanni, Boschello, Filippo, Strizzolo, Stefania, Gardellin, Francesco, Di Giannantonio, Massimo, Fizzotti, Carlo, Cossetta, Edoardo, Di Gregorio, Luana, Sozzi, Francesca, Boncompagni, Giancarlo, La Barbera, Daniele, Colli, Giuseppe, Laurenzi, Sabrina, Luca, Maria, D'Agostino A., Aguglia A., Barbui C., Bartoli F., Carra G., Cavallotti S., Chirico M., Ostinelli E.G., Zangani C., Martinotti G., Ostuzzi G., Nose M., Purgato M., Turrini G., Mazzi M.A., Papola D., Gastaldon C., Terlizzi S., Bertolini F., Piccoli A., Ruggeri M., De Fazio P., Magliocco F., Caroleo M., Raffaele G., Bergamelli E., Lucii C., Bolognesi S., Debolini S., Pierantozzi E., Fargnoli F., Del Zanna M., Giannini A., Luccarelli L., De Capua A., Annese P.M., Cerretini M., Tozzi F., Magnani N., Cardamone G., Bardicchia F., Facchi E., Soscia F., Zotos S., Biancosino B., Zonta F., Pompei F., Callegari C., Zizolfi D., Poloni N., Ielmini M., Caselli I., Giana E., Buzzi A., Diurni M., Milano A., Sani E., Calzolari R., Bortolaso P., Piccinelli M., Cazzamalli S., Alberini G., Piantanida S., Costantini C., Paronelli C., Di Caro A., Moretti V., Gozzi M., D'Ippolito C., Barbanti S.V., Alessandro P., Corbo M., Campese O., Fiori F., Lorusso M., Di Capro L., Viceconte D., Mancini V., Suraniti F., Signorelli M.S., Rossi E., Lupoli P., Menchetti M., Terzi L., Boso M., Risaro P., De Paoli G., Catania C., Tarricone I., Caretto V., Storbini V., Emiliani R., Balzarro B., Tabacchi T., Nava R., Bono A., Provenzi M., Brambilla G., Aspesi F., Trotta G., Tremolada M., Castagna G., Bava M., Verrengia E., Lucchi S., Oriani M.G., Barchiesi M., Pacetti M., Amerio A., Amore M., Serafini G., Magni L.R., Rossi G., Beneduce R., Tura G.B., Laffranchini L., Mastromo D., Ferrato F., Restaino F., Monzani E., Porcellana M., Limosani I., Ghio L., Ferro M., Parise V.F., Balletta G., Addeo L., De Vivo E., Di Benedetto R., Pinna F., Carpiniello B., Spano M., Giacomin M., Pecile D., Mattei C., Fabrici E.P., Panarello S., Peresson G., Vitucci C., Bonavigo T., Perini G., Boschello F., Strizzolo S., Gardellin F., di Giannantonio M., Moretti D., Fizzotti C., Cossetta E., Di Gregorio L., Sozzi F., Boncompagni G., La Barbera D., Colli G., Laurenzi S., Calandra C., Luca M., D'Agostino, A, Aguglia, A, Barbui, C, Bartoli, F, Carra, G, Cavallotti, S, Chirico, M, Ostinelli, E, Zangani, C, Martinotti, G, Ostuzzi, G, D'Agostino, Armando, Aguglia, Andrea, Barbui, Corrado, Bartoli, Francesco, Carrà, Giuseppe, Cavallotti, Simone, Chirico, Margherita, Ostinelli, Edoardo G, Zangani, Caroline, Martinotti, Giovanni, Ostuzzi, Giovanni, and LA BARBERA, DANIELE

Subjects
Long-acting injectable antipsychotic, Cross-Sectional Studies, Off-label, Personality disorder, Bipolar disorder, Delayed-Action Preparations, Schizophrenia, Humans, Long-acting injectable antipsychotics, Off-Label Use, Antipsychotic Agents, Settore MED/25 - Psichiatria
Abstract

Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on– vs off–label LAIs and predictors of off–label First– or Second–Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off– or on–label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with the choice of FGA vs SGA prescription in the off–label group. Results: SGA LAIs were more commonly prescribed in everyday practice, without significant differences in their on– and off–label use. Approximately 1 in 4 patients received an off–label prescription. In the off–label group, the most frequent diagnoses were bipolar disorder (67.5%) or any personality disorder (23.7%). FGA vs SGA LAI choice was significantly associated with BPRS thought disorder (OR = 1.22, CI95% 1.04 to 1.43, p= 0.015) and hostility/suspiciousness (OR = 0.83, CI95% 0.71 to 0.97, p= 0.017) dimensions. The likelihood of receiving an SGA LAI grew steadily with the increase of the BPRS thought disturbance score. Conversely, a preference towards prescribing an FGA was observed with higher scores at the BPRS hostility/suspiciousness subscale. Conclusion: Our study is the first to identify predictors of FGA vs SGA choice in patients treated with off–label LAI antipsychotics. Demographic characteristics, i.e. age, sex, and substance/alcohol use co–morbidities did not appear to influence the choice towards FGAs or SGAs. Despite a lack of evidence, clinicians tend to favour FGA over SGA LAIs in bipolar or personality disorder patients with relevant hostility. Further research is needed to evaluate treatment adherence and clinical effectiveness of these prescriptive patterns.

Published
2022

26. Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review

Author

Zangani, Caroline, primary, Ostinelli, Edoardo G, additional, Smith, Katharine A, additional, Hong, James S W, additional, Macdonald, Orla, additional, Reen, Gurpreet, additional, Reid, Katherine, additional, Vincent, Charles, additional, Syed Sheriff, Rebecca, additional, Harrison, Paul J, additional, Hawton, Keith, additional, Pitman, Alexandra, additional, Bale, Rob, additional, Fazel, Seena, additional, Geddes, John R, additional, and Cipriani, Andrea, additional

Published
2022
Full Text
View/download PDF

29. Mental health services, tele-mental health, and COVID-19: a systematic review of the worldwide picture (Preprint)

Author

Zangani, Caroline, primary, Ostinelli, Edoardo G, additional, Smith, Katharine A, additional, Hong, James SW, additional, Macdonald, Orla, additional, Reen, Gurpreet, additional, Reid, Katherine, additional, Vincent, Charles, additional, Sheriff, Rebecca, additional, Harrison, Paul J, additional, Hawton, Keith, additional, Pitman, Alexandra, additional, Bale, Rob, additional, Fazel, Seena, additional, Geddes, John R, additional, and Cipriani, Andrea, additional

Published
2022
Full Text
View/download PDF

32. Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis

Author

Furukawa, Yuki, Oguro, Saki, Obata, Satomi, Hamza, Tasnim, Ostinelli, Edoardo G, and Kasai, Kiyoto

Subjects
610 Medicine & health, 360 Social problems & social services
Abstract

BACKGROUND Brexpiprazole augmentation is an effective treatment strategy for antidepressant-refractory depression, but its optimal dosage remains unclear. AIMS To find the optimal dosage of brexpiprazole as augmentation of other antidepressants. METHODS We searched multiple electronic databases (from inception to September 16th, 2021) to identify double-blind, randomized placebo-controlled fixed-dose trials evaluating brexpiprazole augmentation therapy in adults (≥18 years old, both genders) with major depressive disorder not adequately responding to one or more antidepressant treatment. Our outcomes of interest at 8 weeks (range 4-12 weeks) were efficacy (treatment response defined as 50% or greater reduction in depression severity), tolerability (dropouts due to adverse effects) and acceptability (dropouts for any reason). We performed a random-effects, one-stage dose-effect meta-analysis with restricted cubic splines. RESULTS Six studies met the inclusion criteria, including 1,671 participants in total. The dose-efficacy curve showed an increase up to doses around 2 mg (odds ratio [OR] 1.52, 95% confidence interval [CI] 1.12-2.06) and then a decreasing trend through the higher licensed dose up to 3 mg (OR 1.40, 95%CI 0.95-2.08). The shape of the dose-tolerability curve was comparable to that of the efficacy and the dose-acceptability curve showed a monotonic increasing trend but both had wide confidence bands. CONCLUSIONS One to two mg of brexpiprazole as augmentation treatment may achieve an optimal balance between efficacy, tolerability, and acceptability in the acute treatment of antidepressant-refractory depression. However, the small number of included studies limit the reliability of the results. Further research is required to validate the findings. This article is protected by copyright. All rights reserved.

Published
2022
Full Text
View/download PDF

37. Dismantling, optimising and personalising internet cognitive-behavioural therapy for depression : A systematic review and individual participant data component network meta-analysis

Author

Furukawa, Toshi A, Suganuma, Aya, Ostinelli, Edoardo G., Andersson, Gerhard, Beevers, Christopher G., Shumake, Jason, Berger, Thomas, Boele, Florien Willemijn, Buntrock, Claudia, Carlbring, Per, Choi, Isabella, Christensen, Heleen, Mackinnon, Andrew, Dahne, Jennifer, Huibers, Marcus J.H., D. Ebert, David, Farrer, Louise, Forand, Nicholas R., Strunk, Daniel R., Ezawa, Ionu D., Forsell, Erik, Kaldo, Viktor, Geraedts, Anna, Gilbody, Simon, Littlewood, Liz, Brabyn, Sally, Hadjistavropoulos, Heather D., Schneider, Luke H., Johansson, Robert, Kenter, Robin, Kivi, Marie, Björkelund, Cecilia, Kleiboer, Annet, Riper, Heleen, Klein, Jan Philipp, Schröder, Johanna, Meyer, Björn, Moritz, Steffen, Bücker, Lara, Lintvedt, Ove, Lundgren, Johan, Milgrom, Jeannette, Gemmill, Alan W., Mohr, David C., Montero-Marin, Jesus, Garcia- Campayo, Javier, Nobis, Stephanie, Zarski, Anna-Carlotta, O'Moore, Kathleen, D. Williams, Alishia, Newby, Jill M., Perini, Sarah, Phillips, Rachel, Schneider, Justine, Pots, Wendy, Pugh, Nicole E, Richards, Derek, M. Rosso, Isabelle, Rauch, Scott L., Sheeber, Lisa B., Smith, Jessica, Spek, Viola, Pop, Viktor J., Ünlü, Burçin, van Bastelaar, Kim M. P., van Luenen, Sanne, Garnefski, Nadia, Vernmark, Kristofer, Warmerdam, Lisanne, van Straten, Annemieke, Zagorscak, Pavle, Knaevelsrud, Christine, Heinrich, Manuel, Miguel, Clara, Cipriani, Andrea, Efthimiou, Orestis, Karyotaki, Eirini, and Cuijpers, Pim

Published
2021

38. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta‐analysis

Author

Furukawa, Toshi A., primary, Shinohara, Kiyomi, additional, Sahker, Ethan, additional, Karyotaki, Eirini, additional, Miguel, Clara, additional, Ciharova, Marketa, additional, Bockting, Claudi L.H., additional, Breedvelt, Josefien J.F., additional, Tajika, Aran, additional, Imai, Hissei, additional, Ostinelli, Edoardo G., additional, Sakata, Masatsugu, additional, Toyomoto, Rie, additional, Kishimoto, Sanae, additional, Ito, Masami, additional, Furukawa, Yuki, additional, Cipriani, Andrea, additional, Hollon, Steven D., additional, and Cuijpers, Pim, additional

Published
2021
Full Text
View/download PDF

39. Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis.

Author

Furukawa, Yuki, Hamza, Tasnim, Cipriani, Andrea, Furukawa, Toshi A., Salanti, Georgia, and Ostinelli, Edoardo G.

Subjects
ANTIDEPRESSANTS, RESEARCH evaluation, META-analysis, SYSTEMATIC reviews, MENTAL depression
Abstract

Background: Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wide and optimal dosage remains unclear.Aims: To find the optimal dosage of aripiprazole augmentation.Method: Multiple electronic databases were searched (from inception to 16 February 2021) to identify all assessor-masked randomised controlled trials evaluating aripiprazole augmentation therapy in adults (≥18 years old, both genders) with major depressive disorder showing inadequate response to at least one antidepressant treatment. A random-effects, one-stage dose-effect meta-analysis with restricted cubic splines was conducted. Outcomes were efficacy (treatment response: ≥50% reduction in depression severity), tolerability (drop-out due to adverse effects) and acceptability (drop-out for any reason) after 8 weeks of treatment (range 4-12 weeks).Results: Ten studies met the inclusion criteria. All were individually randomised, placebo-controlled, multi-centre, parallel studies including 2625 participants in total. The maximum target dose-efficacy curve showed an increase up to doses between 2 mg (odds ratio OR = 1.46, 95% CI 1.15-1.85) and 5 mg (OR = 1.93, 95% CI 1.33-2.81), and then a non-increasing trend through the higher licensed doses up to 20 mg (OR = 1.90, 95% CI 1.52-2.37). Tolerability showed a similar trend with greater uncertainty. Acceptability showed no significant difference through the examined dose range. Certainty of evidence was low to moderate.Conclusions: Low-dose aripiprazole as augmentation treatment might achieve the optimal balance between efficacy, tolerability and acceptability in the acute treatment of antidepressant-refractory depression. However, the small number of included studies and the overall moderate to high risk of bias seriously compromise the reliability of the results. Further research is required to investigate the benefits of low versus high dose. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review

Author

Correll, Christoph U., primary, Cortese, Samuele, additional, Croatto, Giovanni, additional, Monaco, Francesco, additional, Krinitski, Damir, additional, Arrondo, Gonzalo, additional, Ostinelli, Edoardo G., additional, Zangani, Caroline, additional, Fornaro, Michele, additional, Estradé, Andrés, additional, Fusar‐Poli, Paolo, additional, Carvalho, Andre F., additional, and Solmi, Marco, additional

Published
2021
Full Text
View/download PDF

41. Substance use disorder treatment success: assessing patient-reported use improvement and provider-evaluated treatment completion.

Author

Sahker, Ethan, Onishi, Akira, Ostinelli, Edoardo G., Tsutsumi, Yusuke, Omae, Kenji, and Furukawa, Toshi A.

Subjects
SUBSTANCE abuse treatment, CONSENSUS (Social sciences), CONFIDENCE intervals, CROSS-sectional method, HEALTH outcome assessment, RETROSPECTIVE studies, TREATMENT effectiveness, CONFLICT of interests, DESCRIPTIVE statistics, MEDICAL referrals, EMPLOYMENT, SUPPORT groups, PATIENT-professional relations, LOGISTIC regression analysis, EVALUATION
Abstract

Provider-evaluated substance use treatment completion and client-reported substance use improvement are standards in determining treatment success. The relationship between these two outcomes is anecdotally understood in practice. However, the relationship has not been empirically determined and factors related to provider/client conflicting assessments are unknown. This study investigates treatment success by investigating consensus and conflict between improvement and completion in a large national sample. The present study is a cross-sectional retrospective evaluation of US substance use treatment episodes from facilities receiving public funding from 2015 to 2019 (N = 5,047,714). Episodes were mostly male (64.5%), aged 25–34 (34.4%), and White (58.5%). Conflict, consensus, and client factors associated with conflicting outcome evaluations were compared with differences in proportions and their 95% confidence intervals. Logistic regression was used to predict completion from improvement, adjusting for covariates. For absolute percentages, clients and providers were in consensus in 48.3% of all episodes, 32.5% were in conflict, and 19.2% were missing. The adjusted analysis significantly predicted completion from improvement (aOR = 2.18, 95% CI = 2.17, 2.19). Importantly, outcome conflict demonstrated absolute meaningful associations with problem substance, referral source, employment status, service setting, and supplemental mutual-help group attendance. Completion and improvement are somewhat associated, but most likely represent separate factors of treatment success. Addressing factors associated with outcome conflict may improve client and provider consensus and increase successful recovery. Policies and programs can set standards aligned with a uniform definition of success accounting for use improvement. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta‐review of 78 adverse effects

Author

Solmi, Marco, primary, Fornaro, Michele, additional, Ostinelli, Edoardo G., additional, Zangani, Caroline, additional, Croatto, Giovanni, additional, Monaco, Francesco, additional, Krinitski, Damir, additional, Fusar‐Poli, Paolo, additional, and Correll, Christoph U., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results